Public Research

  • |

    The Public Helped Prove Remdesivir—Then Got the Invoice

    ByPhil McCracken

    I follow the invoice, and Remdesivir leads straight to the strangest line item in pandemic economics: public support helping carry the research risk while Gilead’s approximately $3,120 list-price headline arrives like the taxpayer has never met the taxpayer. That figure was not necessarily every patient’s final bill, and public funding did not pay for every step of the work. But the fairness problem remains plain: when public money helps steady the ladder, private billing should not act like it built the building alone.

    America gets cast as both venture capitalist and customer—asked to help finance the uncertain part, then sent shopping at the counter once the emergency treatment is ready. The money trail wore cologne, but the receipt still smells like a double charge: first as research backer, then as buyer. If public science helps make a medical breakthrough possible, why does the public receive so little leverage over the price and so much responsibility for paying it?

  • |

    Your Phone Was Publicly Funded; Apple Sends the Rent

    ByLee Keybum

    Some of the smartphone’s essential toolkit grew from public research: networking, GPS, touch technology, and voice systems all benefited from government or university work. Then Apple arrived with excellent design, tight integration, and the confidence of a landlord who discovered marble. Suddenly the public foundation became invisible scenery behind a private miracle.

    Apple deserves credit for turning complicated tools into a product people actually want to use. But “we made it beautiful” is not the same as “we invented the whole toolbox.” Taxpayers helped raise the building; Apple added a luxury lobby, installed a platform toll booth, and started charging admission to the elevator. The museum gift shop now has a subscription barnacle, and somehow the receipt still says innovation.

  • |

    Public Grants, Private Tollbooth: Who Pays Twice for Xtandi?

    ByPhil McCracken

    At my invoice desk, the Xtandi money trail arrives wearing a lab coat and leaves in a limousine. The complaint is straightforward: public funding helped support UCLA-linked research, while commercialization and patent control became associated with Astellas and Pfizer. Then patients encountered annual U.S. price claims reaching roughly $160,000 to $180,000. That is a remarkable billing arrangement—taxpayers help finance the road, private interests control the toll gate, and the patient gets charged for driving on it.

    Not every stage of Xtandi’s development can be reduced to one public grant or one private decision, and a list price is not the same as every patient’s bill. But the public-return question remains as stubborn as a bad line item: when public science helps move an essential medicine forward, what does the public receive besides another invoice? Innovation may begin as public service, yet somehow ends as private property with a collections department. Follow the invoice long enough and it reaches the same destination: the patient, standing at the pharmacy counter with the receipt and no lobbyist’s expense account.

  • |

    We Fund the Science. They Set the $3.95 Million Price.

    ByPhil McCracken

    I followed the Kebilidi invoice and found NIH’s NCATS on the public-science side, PTC Therapeutics at the commercial finish line, and a stated price of $3.95 million waiting like it had its own congressional parking space. That does not mean public research invented every molecule or erased the company’s costs. It does mean taxpayers and patients deserve a seat at the pricing table when public support helped move a rare-disease therapy from scientific risk toward treatment.

    One-time gene therapies are complex and expensive; nobody is asking the lab to accept payment in inspirational refrigerator magnets. But complexity cannot be the magic word that makes public investment disappear from the conversation. The public helped build the runway, while private billing arrived dressed as the sole owner of aviation. Follow the invoice: government may not have created every part of Kebilidi, but families should not be treated like silent partners who receive only the receipt. Fair pricing and fair taxes are the minimum decent terms.

  • |

    Medicare’s Taxpayer-Funded Layaway Plan

    ByHarlan Quill

    At the courthouse-basement level of policy math, the arrangement is hard to defend: taxpayers help absorb the early risk of medical discovery, then a private patent can put the finished medicine behind a padlock while Medicare and patients meet the checkout price.

    That is a taxpayer-funded layaway plan. We help finance the scientific groundwork, a company controls the bottle, and the public returns to retrieve its medicine with a bill wearing a shareholder-return hat. If public support helps make a breakthrough possible, public policy should at least ask what public value comes back. Otherwise, we did not merely buy the breakthrough; we rented it back from the company that put a padlock on the bottle.

  • |

    Skysona and the $3 Million Toll Booth

    ByPhil McCracken

    I audit public-private invoices for a living, and Skysona arrives looking like a federal infrastructure project with a very expensive toll booth. The premise is straightforward: NIH support, academic medical centers, and basic research helped build the gene-therapy road, while bluebird bio brought a finished treatment to market with a $3 million price tag. Rare-disease therapies are complex, and private development matters. Fine. Complexity is not a magic eraser for the public role.

    The money trail deserves more than an innovation ribbon-cutting. If taxpayers and public institutions carried part of the long, uncertain research burden, patients and families are entitled to ask what public return comes with the private invoice. Nobody is claiming bluebird bio did nothing; the question is who absorbed the early risk and who gets the reward when science becomes a product. Taxpayers helped pave the road. Calling the toll booth innovation does not make the receipt disappear.

End of content

End of content